Results 171 to 180 of about 21,018 (198)

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Blood
Burger JA, Barr PM, Robak T, Owen C, Tedeschi A, Sarma A, Patten PEM, Grosicki S, McCarthy H, Offner F, Szafer-Glusman E, Zhou C, Szoke A, Neumayr L, Dean JP, Ghia P, Kipps TJ.   +16 more
europepmc   +1 more source

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model-Informed Dosing Recommendations for Anticancer Drugs. [PDF]

CPT Pharmacometrics Syst Pharmacol
Goosen TC, Wu X, Lin J, Cheruvu N, Raber SR, de Figueiredo MLN, Varma MVS.   +6 more
europepmc   +1 more source

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs. [PDF]

J Clin Med
Robak T, Iskierka-Jażdżewska E, Puła A, Robak P, Puła B.   +4 more
europepmc   +1 more source

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression. [PDF]

Blood Cancer J
Tantawy SI, Aslan B, Manyam G, Iles LR, Timofeeva N, Singh N, Jain N, Ferrajoli A, Thompson PA, Patel KP, Desikan SP, Wierda WG, Gandhi V.   +12 more
europepmc   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]

Blood Cancer J
Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

Nature Medicine, 2018
Rishu Agarwal, Yih-Chih Chan, Constantine S Tam   +2 more
exaly  

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

Cancer Discovery, 2017
Christian Grommes, Alessandro Pastore, Nicolaos J Palaskas   +2 more
exaly